GlassScriptPhysician profile
Susan Danielle Beitzell
NPI 1134639347
$13,159.21
in general payments reported to CMS, 2019-2025
37 companies · $3,994 in 2025
The $3,994 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,143 · 2022: $2,190 · 2023: $2,479 · 2024: $3,352 · 2025: $3,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,825.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,797.53 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,026.18 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $929.28 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $656.40 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $626.60 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $580.62 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $471.30 | 2022-2025 | Dupixent |
| Pfizer INC. | $468.82 | 2023-2025 | |
| Celgene Corporation | $444.14 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $393.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $377.45 | 2021-2024 | Ocaliva |
| Lilly USA, LLC | $284.21 | 2023-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $280.96 | 2021-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $189.77 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $166.87 | 2024-2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $159.20 | 2025 | Terlivaz |
| Boston Scientific Corporation | $154.15 | 2025 | Watchman Flx, General - Therapies |
| Ironwood Pharmaceuticals, INC | $126.36 | 2021-2024 | Linzess |
| Organon LLC | $108.64 | 2024-2025 | Hadlima, Renflexis |
| Merck Sharp & Dohme LLC | $91.20 | 2021-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $82.24 | 2021-2023 | Rebyota |
| Sandoz INC. | $82.05 | 2023-2024 | Hyrimoz |
| Gilead Sciences, INC. | $79.76 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.15 | 2023 | Zeposia |
| Celltrion USA INC. | $74.02 | 2024-2025 | Vegzelma, Zymfentra |
| Vivus LLC | $69.47 | 2021-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $65.22 | 2023-2025 | Zenpep |
| Amgen INC. | $52.55 | 2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $52.24 | 2021-2023 | |
| Evoke Pharma, INC. | $41.01 | 2021-2023 | Gimoti |
| Novo Nordisk INC | $32.33 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $32.00 | 2025 | Suflave, Sutab |
| Fresenius Kabi USA, LLC | $31.55 | 2023 | |
| Janssen Scientific Affairs, LLC | $24.64 | 2023-2025 | Stelara, Tremfya |
| Medtronic, INC. | $13.77 | 2025 | Interstim |
| Mauna Kea Technologies, INC. | $10.35 | 2023 | |
| Intra-Sana Laboratories | $3.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Beitzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.